ACTA NEUROBIOLOGIAE EXPERIMENTALIS, an esteemed journal published by the Nencki Institute of Experimental Biology in Poland, has been a pivotal platform for the dissemination of research in the fields of medicine and neuroscience since its inception in 1970. With an ISSN of 0065-1400 and an E-ISSN of 1689-0035, this journal has consistently aimed to contribute to the understanding of neurobiological phenomena, cementing its status within the academic community. Despite its current categorization in the Q3 and Q4 quartiles for Medicine and Neuroscience respectively, ACTA NEUROBIOLOGIAE EXPERIMENTALIS continues to uphold rigorous scientific standards, providing an invaluable resource for researchers, professionals, and students alike. As an essential scholarly outlet, it encourages the exploration of groundbreaking findings and clinical applications in neurobiology, making it an attractive choice for those eager to advance their understanding of this intricate field.

JOURNAL OF MOLECULAR MEDICINE (JMM) is a premier publication dedicated to advancing the field of molecular medicine, encompassing critical areas such as drug discovery, genetics, and biochemistry. Published by Springer Heidelberg in Germany, this influential journal has established its significance within the academic community, achieving an impressive Q1 ranking across multiple categories as of 2023, including Drug Discovery, Clinical Genetics, and Molecular Medicine. With a focus on publishing high-quality research and novel insights, JMM appeals to a diverse audience of researchers, professionals, and students passionate about the molecular underpinnings of health and disease. The journal, which has seen a convergence of relevant research spanning from 1976 to 2024, is instrumental in showcasing groundbreaking studies that push the boundaries of knowledge in molecular therapeutics and biomedical science. While it does not offer open access, the rigor of its peer-reviewed content ensures that each publication is a valuable addition to the scientific discourse surrounding molecular medicine. For comprehensive studies and reviews that highlight the intersection of molecular biology and clinical application, look no further than JOURNAL OF MOLECULAR MEDICINE.

Welcome to the Journal of Central Nervous System Disease, a premier Open Access publication dedicated to advancing the understanding of neurological disorders and their underlying mechanisms. Published by SAGE Publications Ltd, this esteemed journal has been serving the scientific community since 2009 and is committed to disseminating high-quality research that spans from clinical neurology to cellular and molecular neuroscience. With an impressive impact factor, the journal ranks within the top quartiles—Q2 in both Neurology and Clinical Neurology, and Q3 in Cellular and Molecular Neuroscience as of 2023. The journal's indexing in Scopus reflects its significant contribution to the field, being ranked #83 out of 400 in clinical neurology and #38 out of 97 in cellular and molecular neuroscience. This essential resource, based in the United States, is crucial for researchers, clinicians, and students looking to stay at the forefront of neurological science. By providing Open Access options, we ensure that groundbreaking research is readily available to a global audience, fostering collaboration and innovation in the study of central nervous system diseases.

Frontiers in Molecular Neuroscience, published by FRONTIERS MEDIA SA, is an esteemed open-access journal dedicated to advancing our understanding of the molecular mechanisms underlying neurological functions and disorders. Since its inception in 2008, the journal has established itself as a reputable source of cutting-edge research, earning a respectable Q2 ranking in both the fields of Cellular and Molecular Neuroscience and Molecular Biology as of 2023. With an ongoing commitment to fostering innovation, the journal presents a platform for researchers, professionals, and students to disseminate their findings and engage in scholarly discourse. The E-ISSN 1662-5099 ensures that research is readily accessible, facilitating the exchange of knowledge crucial to tackling the complexities of neurological conditions. Situated in Switzerland, the journal’s global reach is augmented by its open-access model, allowing for wide dissemination of critical research findings to a diverse audience. Join the vibrant community of scientists and practitioners who are shaping the future of molecular neuroscience through their contributions to this dynamic journal.

CNS & Neurological Disorders-Drug Targets is a distinguished journal that focuses on contemporary research and advancements in the realms of neurology, pharmacology, and drug development. Published by Bentham Science Publishers, this journal serves as an essential platform for researchers, professionals, and students interested in the intricate workings of the central nervous system and the evolving strategies to target neurological disorders through pharmacological innovations. With a robust impact factor reflecting its academic relevance, CNS & Neurological Disorders-Drug Targets is categorized in the Q2 quartile for both Medicine (miscellaneous) and Pharmacology, and Q3 for Neuroscience in the 2023 rankings. The journal's Scopus rankings further reinforce its authority, positioning it within the top half of its categories. Operating out of the United Arab Emirates, the journal has been a loyal contributor to the scientific discourse since its inception in 2006 and will continue until at least 2024, ensuring a dynamic channel for the latest findings and reviews in this vital field. As an open-access publication, it prioritizes accessibility, thus fostering a wider impact among scholars and practitioners alike, making it a valuable resource for all stakeholders in neurological and pharmacological research.

ACS Chemical Neuroscience, published by the American Chemical Society, is a premier journal dedicated to exploring the complex interactions between chemistry and neuroscience. With its ISSN 1948-7193 and a distinguished impact factor that positions it within the top quartiles across multiple categories, including Q1 in Biochemistry, Q2 in Cell Biology, and Q1 in Physiology, this journal serves as an essential platform for researchers engaged in cutting-edge studies from 2010 to 2024. Positioned within the top 15% of its field in Cognitive Neuroscience according to Scopus rankings, ACS Chemical Neuroscience strives to foster interdisciplinary collaboration, publishing significant advancements that integrate chemical concepts with neurological processes. Despite its traditional publication model, the journal is committed to maintaining rigorous peer-review standards and providing valuable insights that drive innovations in therapeutics and understanding the biochemical underpinnings of brain function. Researchers, professionals, and students alike will find in this journal a vital resource for the latest findings and methodologies in the dynamic intersection of chemistry and neuroscience.

Neural Regeneration Research is a premier Open Access journal, published by Wolters Kluwer Medknow Publications, dedicated to advancing the field of Developmental Neuroscience. Since its inception, the journal has established itself as a valuable resource for researchers, professionals, and students alike, providing a comprehensive platform for disseminating the latest findings and methodologies in neural regeneration. With an impressive Scopus Ranks placement of #3 out of 49 in its category and a Q2 Quartile ranking, the journal boasts a significant impact within the academic community, reflecting its high quality and relevance. Since adopting an Open Access model in 2011, it has expanded access to critical research in neural regeneration, fostering collaboration and innovation among scholars globally. Covering various aspects of neuroscience, its converged years from 2006 to 2025 highlight the journal's commitment to ongoing discourse and discovery. Situated in China, the journal not only promotes local insights but also connects the global research community to pressing topics in neuroscience, making it an essential read for anyone involved in this dynamic field.

CELLULAR AND MOLECULAR NEUROBIOLOGY, published by SPRINGER/PLENUM PUBLISHERS, stands as a significant contributor to the fields of cell biology and neuroscience, holding a distinguished position in the academic community with an impact factor that places it in the Q2 category for both Cell Biology and Cellular and Molecular Neuroscience, along with Q1 in Medicine (miscellaneous). Since its inception in 1981, this journal has provided a critical platform for innovative research and thought-provoking reviews, fostering a deeper understanding of complex neurobiological mechanisms. The journal’s rigorous peer-review process ensures the publication of high-quality manuscripts that offer valuable insights into cellular processes and neural functions. With a commitment to advancing knowledge and promoting collaboration among researchers, CELLULAR AND MOLECULAR NEUROBIOLOGY remains an essential resource for professionals and students alike, looking to stay updated on the latest developments in neurobiology.

Journal of Molecular Neuroscience, published by SpringerNature, is a critical resource for researchers and professionals in the dynamic field of neuroscience. With ISSN 0895-8696 and E-ISSN 1559-1166, this journal has established itself as a key player since its inception in 1989, covering a range of topics within Cellular and Molecular Neuroscience and Medicine (miscellaneous). Its impressive rankings, including being placed in the Q2 quartile for Medicine and Q3 for Cellular and Molecular Neuroscience, underscore its scholarly impact, featuring innovative research that informs and advances our understanding of neural processes. The journal does not currently operate under an open-access model, providing rich, peer-reviewed content geared towards academics and professionals seeking comprehensive analyses and breakthroughs in molecular neurobiology. With a publication window extending to 2024, the Journal of Molecular Neuroscience remains dedicated to enhancing the scientific community's knowledge landscape, making it an essential reference for those passionate about unraveling the complexities of the nervous system.

ACTA NEUROPATHOLOGICA, published by Springer, is a leading journal in the fields of cellular and molecular neuroscience, clinical neurology, and pathology, recognized for its exceptional quality and impactful research. With an impressive impact factor and currently ranked in the Q1 tier across multiple categories in 2023, this journal serves as a premier platform for the dissemination of groundbreaking findings in neuropathology. The journal's robust Scopus rankings highlight its influence, standing at #2 in Pathology and Forensic Medicine and #5 in Clinical Neurology. Since its inception in 1961, ACTA NEUROPATHOLOGICA has provided crucial insights into neurological diseases and disorders, contributing significantly to the advancement of medical science. Aimed at researchers, practitioners, and students alike, this journal fosters a deeper understanding of neurological conditions and encourages innovative approaches within the field. It is essential reading for anyone dedicated to unraveling the complexities of the nervous system.